"Urate Oxidase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the conversion of urate and unidentified products. It is a copper protein. The initial products decompose to form allantoin. EC 1.7.3.3.
| Descriptor ID |
D014503
|
| MeSH Number(s) |
D08.811.682.943
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Urate Oxidase".
Below are MeSH descriptors whose meaning is more specific than "Urate Oxidase".
This graph shows the total number of publications written about "Urate Oxidase" by people in this website by year, and whether "Urate Oxidase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2005 | 2 | 3 | 5 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Urate Oxidase" by people in Profiles.
-
Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax. Am J Hematol. 2021 03 01; 96(3):E65-E68.
-
Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. Lancet Haematol. 2020 Feb; 7(2):e168-e176.
-
Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. Leuk Res. 2020 02; 89:106298.
-
Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification. J Oncol Pharm Pract. 2020 Apr; 26(3):529-535.
-
Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6- Phosphate Dehydrogenase Deficiency. Curr Drug Saf. 2017; 12(1):13-18.
-
Complications of "very high" leukocytosis in pediatric acute leukemia patients managed without rasburicase and leukopheresis. Indian J Pediatr. 2014 Aug; 81(8):817-20.
-
Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis. Am J Kidney Dis. 2013 Sep; 62(3):481-92.
-
Rasburicase for hyperuricemia in hemolytic uremic syndrome. Pediatr Nephrol. 2012 Feb; 27(2):325-9.
-
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 Jun; 23(6):1640-5.
-
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. J Clin Oncol. 2010 Sep 20; 28(27):4207-13.